CN Patent

CN121969369A — Parp-1选择性抑制剂和替莫唑胺的组合及其治疗神经胶质瘤的用途

Assigned to Nerviano Medical Sciences SRL · Expires 2026-05-01 · 0y expired

What this patent protects

Patent listed against Synribo.

Drugs covered by this patent

Patent Metadata

Patent number
CN121969369A
Jurisdiction
CN
Classification
—
Expires
2026-05-01
Drug substance claim
No
Drug product claim
No
Assignee
Nerviano Medical Sciences SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.